文献速递其他结缔组织病

血小板与中性粒细胞协同释放线粒体DNA驱动系统性硬化症干扰素特征

A Cooperative Release of Mitochondrial DNA From Platelets and Neutrophils Drives an Interferon Signature in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2026-03-16

本研究探讨系统性硬化症(SSc)循环DNA的作用及释放机制。SSc患者血浆线粒体DNA(mtDNA)中位水平较健康对照高152倍,且高度氧化;SSc来源mtDNA通过NETosis和血小板活化促进自身释放,并与CXCL4复合进一步刺激释放,血浆mtDNA浓度与I型干扰素浓度相关,SSc血液显示干扰素刺激基因表达升高。mtDNA通过内体Toll样受体、cGAS/STING和JAK/STAT通路诱导干扰素信号和NET形成,I型干扰素通路又促进NETosis和mtDNA释放。

要点

  • SSc患者血浆mtDNA中位水平较健康对照高152倍,核DNA水平相似。
  • SSc来源氧化mtDNA通过NETosis和血小板活化促进自身释放,与CXCL4复合后进一步刺激释放。
  • mtDNA通过内体TLR、cGAS/STING和JAK/STAT通路诱导I型干扰素信号和NET形成。

核心结论

  • SSc血浆以高度丰富的mtDNA为特征,驱动中性粒细胞和血小板释放mtDNA的正反馈环路,参与SSc炎症和组织损伤。

研究设计与样本

  • 从健康对照和SSc患者血浆分离总DNA,用定量实时PCR分析mtDNA(ATP-6)和GAPDH拷贝数。
  • 将中性粒细胞和血小板与SSc患者血浆及mtDNA共孵育,用SytoxGreen和免疫染色评估NET形成。
  • 体外用MitoSOX Red染色评估DNA氧化,用ELISA检测患者血浆8-OHdG、I型干扰素和CXCL4。
  • 用THP-1报告细胞评估干扰素信号激活能力,并通过全血bulk RNA转录组分析确认。

主要发现

  • SSc患者血浆mtDNA中位水平较健康对照高152倍,而核DNA水平相似。
  • SSc血浆mtDNA高度氧化,SSc来源mtDNA有效促进自身通过NETosis释放,在SSc患者中性粒细胞中最强,并通过血小板活化促进释放。
  • SSc血小板中氧化mtDNA与CXCL4复合进一步刺激中性粒细胞和血小板释放mtDNA。
  • 血浆mtDNA浓度与SSc患者血液I型干扰素浓度相关,SSc血液显示干扰素刺激基因表达升高。
  • SSc血浆来源mtDNA通过内体Toll样受体、cGAS/STING和JAK/STAT通路诱导干扰素信号和NET形成;IFN受体和JAK抑制拮抗IFN的促NETosis效应。

临床怎么用

  • SSc患者血浆mtDNA水平显著升高且高度氧化,可作为干扰素通路激活的潜在生物标志物。
  • 靶向mtDNA释放正反馈环路(如JAK/STAT抑制)可能减轻SSc炎症和组织损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release. METHODS: Total DNA was isolated from the plasma of healthy controls (HCs) and patients with SSc. Copy numbers were analyzed for mtDNA (ATP-6) and GAPDH abundance by quantitative real-time polymerase chain reaction. mtDNA was isolated from HCs and patients with SSc. Neutrophils and platelets were incubated with the plasma and mtDNA of patients with SSc, and neutrophil extracellular trap (NET) formation was assessed by SytoxGreen and immunostainings. Platelets were tested for mtDNA release propensity. DNA oxidation was evaluated by MitoSOX Red staining in vitro and 8-OHdG enzyme-linked immunosorbent assay (ELISA) of patient plasma. Plasma interferon (IFN) type 1 and chemokine (C-X-C motif) ligand 4 (CXCL4) were measured by ELISA. IFN signaling activation capacity was evaluated using THP-1 reporter cells and confirmed by a whole blood bulk RNA transcriptomic analysis. RESULTS: Median plasma mtDNA levels were 152-fold higher in patients with SSc compared with HCs, whereas nuclear DNA levels were similar. mtDNA from SSc plasma was highly oxidized. SSc-derived mtDNA efficiently promoted its own release by NETosis, most potently in the neutrophils of patients with SSc and by platelet activation. Oxidized mtDNA from SSc platelets in complex with CXCL4 further stimulated mtDNA release in both neutrophils and platelets. mtDNA plasma concentrations correlated with type I IFN concentrations in the blood of patients with SSc, and SSc blood exhibited elevated IFN-stimulated gene expression. SSc plasma-derived mtDNA-induced IFN signaling and NET formation via endosomal Toll-like receptors, cyclic GMP-AMP synthase/stimulator of IFN genes, and the JAK/STAT pathway. The type I IFN pathway further promoted NETosis and mtDNA release because IFN receptor and JAK inhibition antagonized the proNETotic effects of IFN. CONCLUSION: SSc plasma is characterized by highly abundant mtDNA, which drives feedback loops amplifying its own release from both neutrophils and platelets. Thus, mtDNA contributes to inflammation and tissue damage in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Giaglis S, Tiaden AN, Häner-Massimi S, et al. A Cooperative Release of Mitochondrial DNA From Platelets and Neutrophils Drives an Interferon Signature in Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 41412968. doi:10.1002/art.70027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。